slide1
Download
Skip this Video
Download Presentation
Approach to HIV Treatment and Care in Future IPM Microbicide Trials Pam Norick, Chief of External Relations 19 June 200

Loading in 2 Seconds...

play fullscreen
1 / 13

Approach to HIV Treatment and Care in Future IPM Microbicide Trials Pam Norick, Chief of External Relations 19 June 200 - PowerPoint PPT Presentation


  • 132 Views
  • Uploaded on

Approach to HIV Treatment and Care in Future IPM Microbicide Trials Pam Norick, Chief of External Relations 19 June 2008. IPM Mission. Established in 2002 as a non-profit product development partnership Offices in the US, Belgium and South Africa.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Approach to HIV Treatment and Care in Future IPM Microbicide Trials Pam Norick, Chief of External Relations 19 June 200' - hila


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
Approach to HIV Treatment and Care

in Future IPM Microbicide Trials

Pam Norick, Chief of External Relations

19 June 2008

ipm mission
IPM Mission
  • Established in 2002 as a non-profitproduct development partnership
  • Offices in the US, Belgium and South Africa
  • Mission to prevent HIV transmission by accelerating the development and availability of safe and effective microbicides for use by women in developing countries
ipm donors
IPM Donors
  • Sweden
  • United Kingdom
  • United States
  • European Commission
  • World Bank
  • UNFPA
  • Rockefeller Foundation
  • Gates Foundation
  • Belgium
  • Canada
  • Denmark
  • France
  • Germany
  • Ireland
  • Netherlands
  • Norway
ipm clinical studies of dapivirine
IPM Clinical Studies of Dapivirine

PK

PK/Feasibility

Safety/

Feasibility

Safety

2008

2009

2007-08

2004-05

2005-06

Safety

Safety

Safety

Male

tolerance

PK

Phase III efficacy

Seroconverter protocol

Studies in Africa, Europe, United States

slide6
IPM work in Africa

Completed or ongoing studies and activities

Possible activity

ethical guidelines for clinical trials
Ethical Guidelines for Clinical Trials
  • Community engagement
    • Monitoring of social harms
  • Informed consent process
  • Risk reduction counseling
    • Male/female condoms
  • Family planning
    • Management of pregnancy
  • STI screening and treatment
  • Testing positive at screening
    • Counseling and Rx referrals
  • Participants who seroconvert
    • Counseling and Rx referrals
    • Follow-up study protocol
    • Partnerships/dedicated financing
  • Treatment for physical harms
  • Services for study staff
  • Post-trial access to products
ethical guidelines updates
Ethical Guidelines Updates
  • First developed in 2005-06
    • Review by ethicists, stakeholders
  • Revisions in 2007-08
    • Consistent with latest UNAIDS, WHO and country guidelines
    • Document refers principally to clinical trials in developing world
  • Currently under external review
    • Expected publication July 2008
seroconversions ipm trials
Seroconversions – IPM Trials
  • None to date
  • So far conducted Phase I/II safety trials
    • Small sample size (N=130 in Africa)
    • Short enrollment duration (max 6 weeks)
    • Many trials in Belgium (low HIV incidence)
  • Preparing for larger safety trials in Africa
    • IPM 014 A & B (dapivirine gel, N=640, 6 weeks)
    • IPM 015 (dapivirine ring, N=280, 12 weeks)
ipm plans and approach
IPM Plans and Approach

Participants who seroconvert during trials offered appropriate HIV-related care and ARV therapy

  • Plan to implement in multiple ways:
    • Follow-up study (seroconverter protocol – IPM 007)
    • Guided referrals for HIV care, treatment, support
    • Pre-established partnerships with national/local institutions
    • Dedicated financing if national programs cannot sustain
    • Pursuing additional support from global donors
approaches to funding and delivery
Approaches to Funding and Delivery
  • IPM research centres established in areas where capacity for HIV care & treatment exists
    • Part of site selection and development process
  • To assure sustainability, develop partnerships with national ministries of health, hospitals, universities, etc.
  • Dedicated IPM financing in the event national programs cannot assume ongoing responsibility
    • Funds independent of IPM business/financial status
    • Insurance company or other mechanisms
key challenges
Key Challenges
  • Timeframe: participants may not need treatment until years after a trial
  • Migration: how to ensure access for people who move out of the area or country
  • Follow-up: how best to keep in touch with participants & inform them of choices
  • Referral networks: how to ensure their strength over time
  • Sustainability: what is the best approach? (IPM options paper 2007)
pursuing additional support
Pursuing Additional Support
  • PEPFAR
  • Global Fund
  • Clinton Foundation
  • Other microbicide donors
  • Host country governments
    • UNAIDS/WHO recommend that countries include HIV prevention trial participants in their priority list for access to ARV treatment

Ethical Considerations in Biomedical HIV Prevention Trials, 2007

ad